Sera Park

Dr. Sera Park

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JKJintae Kim
Jintae Kim
SPSera Park
Sera Park
DMDongbo Min
Dongbo Min
WKWankyu Kim
Wankyu Kim
Drug discovery based on artificial intelligence has been in the spotlight recently as it significantly reduces the time and cost required for developing novel drugs. With the advancement of deep learning (DL) technology and the growth of drug-related data, numerous deep-learning-based methodologies are emerging at all steps of drug development processes. In particular, pharmaceutical chemists have faced significant issues with regard to selecting and designing potential drugs for a target of interest to enter preclinical testing. The two major challenges are prediction of interactions between drugs and druggable targets and generation of novel molecular structures suitable for a target of interest. Therefore, we reviewed recent deep-learning applications in drug–target interaction (DTI) prediction and de novo drug design. In addition, we introduce a comprehensive summary of a variety of drug and protein representations, DL models, and commonly used benchmark datasets or tools for model training and testing. Finally, we present the remaining challenges for the promising future of DL-based DTI prediction and de novo drug design.

23 February 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
YKYeajee Kwon
Yeajee Kwon
SPSera Park
Sera Park
JLJaeok Lee
Jaeok Lee
JKJiyeon Kang
Jiyeon Kang
HLHwa Jeong Lee
Hwa Jeong Lee
WKWankyu Kim
Wankyu Kim

4 March 2019 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
SPSera Park
Sera Park
YKYeajee Kwon
Yeajee Kwon
HJHyesoo Jung
Hyesoo Jung
SJSukyung Jang
Sukyung Jang
HLHaeseung Lee
Haeseung Lee
WKWankyu Kim
Wankyu Kim
Drug discovery typically involves investigation of a set of compounds (e.g. drug screening hits) in terms of target, disease, and bioactivity. CSgator is a comprehensive analytic tool for set-wise interpretation of compounds. It has two unique analytic features of Compound Set Enrichment Analysis (CSEA) and Compound Cluster Analysis (CCA), which allows batch analysis of compound set in terms of (i) target, (ii) bioactivity, (iii) disease, and (iv) structure. CSEA and CCA present enriched profiles of targets and bioactivities in a compound set, which leads to novel insights on underlying drug mode-of-action, and potential targets. Notably, we propose a novel concept of ‘Hit Enriched Assays”, i.e. bioassays of which hits are enriched among a given set of compounds. As an example, we show its utility in revealing drug mode-of-action or identifying hidden targets for anti-lymphangiogenesis screening hits. CSgator is available at http://csgator.ewha.ac.kr , and most analytic results are downloadable.